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Objective:	 Patients	with	 chronic	 kidney	 disease	 (CKD)	 have	 dysregulated	 cortisol	




activation	of	cortisol	by	11β‐HSD was measured as the metabolite ratio (tetrahydro‐
cortisol	[THF]+5α‐tetrahydrocortisol [5αTHF])/tetrahydrocortisone	(THE)	in	urine.
Results:	The	cohort	included	342	participants	with	a	median	age	of	63	years,	median	








diabetic	 subgroup	 were	 independent	 of	 eGFR,	 C‐reactive	 protein,	 age,	 sex	 and	
ethnicity.
Conclusions:	In	summary,	glucocorticoid	activation	by	11β‐HSD in our cohort com‐
prising	a	spectrum	of	renal	function	was	associated	with	inflammation	and	impaired	
glucose control.
2  |     SAGMEISTER ET Al.
1  | INTRODUC TION
Glucocorticoids	(GCs)	are	steroid	hormones	that	play	a	critical	role	in	
regulating	 energy	metabolism,	 inflammation,	 cardiovascular	 function	
and	behavioural	processes.	In	excess,	GCs	drive	metabolic	disease,	in‐
sulin resistance and cardiovascular disease.1	Critical	 to	the	actions	of	
GCs	are	their	pre‐receptor	metabolism	by	the	11beta‐hydroxysteroid	









metabolites	 (tetrahydrocortisol	 [THF]+5α‐tetrahydrocortisol [5αTHF])/











mation and increases in cortisol activation.12,14	Existing	studies	in	CKD	
have	not	evaluated	 inflammation	as	a	driver	of	11β‐HSD1 activity or 
GC	activation.
The	 inflammatory	 activation	 in	 CKD	 contributes	 to	 insulin	 resis‐




loss	 of	 renal	 function	 and	 death.16,18,19	 Elevated	 11β‐HSD1 activity 
has	 been	 implicated	 in	metabolic	 disease	 and	 insulin	 resistance.23,24 
Suppression	of	11β‐HSD1	activity	protects	against	insulin	resistance	in	
murine	models,	including	models	of	uraemia,	and	has	improved	HbA1c	












2  | MATERIAL S AND METHODS
2.1 | Participants
This	 study	 included	 331	 participants	 with	 CKD	 and	 11	 healthy	
individuals	 without	 kidney	 disease.	 The	 Renal	 Impairment	 in	
Secondary	 Care	 (RIISC)	 observational	 study	 cohort	 provided	
the	 sampling	 frame	 for	 cases	 with	 CKD.	 Patient	 enrolment	 for	
RIISC	took	place	at	two	teaching	hospitals	in	Birmingham,	United	
Kingdom,	 between	 2010	 and	 2015.	 The	 eligibility	 criteria	 have	
been described in detail elsewhere.33	 In	 brief,	 patients	 in	 RIISC	
had	 CKD	 stage	 3	 with	 declining	 estimated	 glomerular	 filtration	
rate	 (eGFR)	 of	 ≥5	mL/min/1.73	m2/y	 or	 ≥10	mL/min/1.73	m2/5 y 
or	proteinuria	with	urinary	albumin‐creatinine	ratio	(ACR)	≥70	mg/
mmol,	 or	 CKD	 stage	 4/5.	 Patients	 receiving	 renal	 replacement	
therapy	 or	 immunosuppressive	 treatment	 were	 excluded	 from	
the	RIISC	cohort.	From	a	 total	of	932	cases	 in	 the	RIISC	cohort,	
299	cases	with	incomplete	biochemical	data	sets	and	25	cases	re‐
ceiving	 systemic	GC	 treatment	were	excluded	prior	 to	 sampling.	
In	 total,	 333	 cases	 of	 608	 eligible	 cases	 were	 sampled	 for	 this	
study	 to	 obtain	 the	 desired	 sample	 size	 (see	 Statistical	 Analysis	
for	 power	 calculation).	 A	 stratified	 random	 sampling	 procedure	












cocorticoid activation by 11β‐HSD,	as	cases	with	normal	renal	func‐
tion	and	no	active	inflammation	are	underrepresented	in	the	RIISC	
cohort.








Study	participants’	 demographic	 information,	 past	medical	 history	
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Laboratory	 measurements	 included	 routine	 blood	 haematologi‐
cal	profiles	(Haematology	Analyser,	Beckman	Coulter,	Brea,	CA,	USA)	
and	 blood	 biochemical	 profiles	 and	 urinary	ACR	 (Roche	Hitachi	 702	
Analyser,	Basel,	Switzerland).	eGFR	was	derived	from	the	serum	cre‐







the	 urinary	 excretion	 of	 (THF+5αTHF)/THE.	 This	 methodology	 is	
well	 established	 as	 reflective	of	11β‐HSD1	activity	 and	has	previ‐
ously	been	validated	in	the	literature,30,31	including	the	use	of	early	
morning	spot	urine	samples.5,34
Spot	 urine	 samples	were	 collected	 at	morning	 clinic	 visits	 and	
stored	at	−80°C	until	analysis.	Steroids	were	extracted	from	400	µL	
of	urine	based	on	a	previously	 reported	protocol.35 The urine was 
spiked	with	0.4	µg	of	internal	standard	(THE‐d5,	THF‐d5;	purchased	
from	Isosciences,	Ambler,	PA,	USA),	and	the	steroids	hydrolysed	to	
remove	 their	 conjugate	groups	 (sulphate	 and/or	 glucuronide).	 This	
was	achieved	by	heating	the	urine	for	3	hours	at	60°C	in	a	hydroly‐
sis	buffer	(400	μL	of	0.2	mol/L	acetate	buffer	pH	4.8‐5:	with	10	mg	





tuted	 in	 125	µL	 of	 50/50	methanol/water	 for	 analysis	with	 liquid	
chromatography‐tandem	mass	spectrometry	(uPLC‐MS/MS).
A	Waters	Xevo	mass	spectrometer	coupled	to	an	Acquity	uPLC	
with	 an	electrospray	 ionization	 source	 in	positive	 ionization	mode	
was	utilized	in	these	experiments.	THE,	THF	and	5αTHF	were	sep‐
arated	on	a	BEH	C18	1.7	µm	5	cm	column	at	60°C	with	the	mobile	






identical	mass	 transitions	 (MRMs)	 required	 for	 positive	 identifica‐
tion	(Supporting	Information	Table	S1	and	Figure	S1).	Steroids	were	
quantified	relative	to	a	calibration	series	ranging	from	10‐5000	ng/
mL	prepared	 in	 synthetic	urine,	 including	a	blank.	Steroid	concen‐















tion	of	 independent	 variables	 and	 log	odds.	 These	were	 therefore	
included	as	log‐transformed	variables	(CRP)	or	as	stratified	variables	
(tertiles	for	urine	(THF+5αTHF)/THE	with	limits	≤0.983,	0.983‐1.586	
and	>1.586;	 clinical	CKD	 stages	 for	 eGFR	with	≤15,	 15‐30,	 30‐45	




to	 a	 baseline	 linear	 regression	model	 for	 urine	 (THF+5αTHF)/THE	







are	 summarized	 in	 Table	 1	 (for	 break‐down	 by	 aetiology	 of	 renal	 
disease	see	Supporting	Information	Table	S3).
3.1 | Renal diagnosis and function
Previous	 studies	 have	 reported	 increasing	 GC	 activation	 by	 11β‐
HSD	enzymes	with	declining	 renal	 function,4,6 which we tested in 
our	 larger	 cohort.	 Urine	 (THF+5αTHF)/THE	was	 elevated	 in	 renal	
disease	regardless	of	aetiology	compared	to	healthy	volunteers,	ex‐
cept	for	polycystic	renal	disease	(Figure	1A).	Among	cases	with	renal	
disease,	 urine	 (THF+5αTHF)/THE	 was	 lowest	 in	 polycystic	 renal	
disease	and	highest	in	diabetic	nephropathy.	As	in	previous	reports,	
we	 found	a	negative	but	weak	 correlation	of	urine	 (THF+5αTHF)/
THE	 with	 eGFR	 (ρ =	−0.116,	 P	=	0.032;	 Figure	 1B).	 There	 was	 no	

























insulin	 signalling,	 but	 this	 has	 not	 yet	 been	 tested	 in	 human	 CKD.	
Having	identified	that	glucocorticoid	activation	by	11β‐HSD is elevated 
in	CKD,	we	examined	the	association	of	urine	(THF+5αTHF)/THE	with	
prevalent	 diabetes.	 Participants	 with	 known	 diabetes	 mellitus	 had	
higher	 urine	 (THF+5αTHF)/THE	 (median	 [interquartile	 range	 (IQR)]:	
1.51	 [0.97‐1.87]	vs	1.14	 [0.81‐1.61],	P	=	0.007;	Figure	3A).	 eGFR	was	
not	significantly	different	between	those	with	or	without	diabetes	(me‐
dian	[IQR]:	26.0	[16.5‐37.3]	vs	29.1	[17.7‐47.5],	P	=	0.142),	but	CRP	was	











3.4 | HbA1c and poor glycaemic control
To	 further	 corroborate	 the	 link	 between	 elevated	 GC	 activation	 by	
11β‐HSD	with	impaired	glucose	metabolism	in	CKD,	we	assessed	the	
relationship	of	GC	activation	by	11β‐HSD	with	HbA1c.	HbA1c	was	pos‐
itively	correlated	with	urine	(THF+5αTHF)/THE	(ρ	=	0.144,	P = 0.008; 
Figure	 3B).	 HbA1c	 also	 exhibited	 a	 negative	 association	 with	 eGFR	
(ρ	=	−0.127,	P	=	0.020)	and	a	positive	association	with	CRP	(ρ	=	0.337,	
P	<	0.001)	 in	our	cohort.	We	controlled	 for	 these	covariates	and	de‐
mographic	factors	 in	a	multiple	 linear	regression	analysis.	Age,	South	
Asian	ethnicity	and	CRP	remained	associated	with	HbA1c	(P	<	0.001,	





as homoeostatic mechanisms that counter‐regulate increased insulin 












Previous	 studies	 in	 patients	 with	 CKD	 have	 suggested	 that	 in‐
creasing	 (THF+5αTHF)/THE	 ratios,	 favouring	 systemic	 cortisol	

























Continuous	 variables	 are	 reported	 as	median	 (interquartile	 range)	 and	
categorical	variables	as	frequency	(percentage).
ACR,	 albumin‐creatinine	 ratio;	 eGFR,	 estimated	 glomerular	 filtration	
rate;	 (THF+5αTHF)/THE,	 tetrahydrocortisol+5α‐tetrahydrocortisol/
tetrahydrocortisone.
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activation,	 are	 determined	 by	 declining	 renal	 function	 and	 at‐
tenuated renal steroid clearance by 11β‐HSD2.4,5	Our	study	con‐
firmed	 that	 GC	 activation	 by	 11β‐HSD	 is	 elevated	 in	 CKD,	 but	




Inflammation,	 measured	 as	 CRP,	 was	 the	 dominant	 explan‐








Previous	 studies	 did	 not	 control	 for	 inflammation,	 which	 is	
concomitant	 with	 renal	 impairment.	 Inflammation	 is	 a	 potent	
inducer	 of	 11β‐HSD1	 expression	 and	 activity,	 with	 significant	
increases in cortisol activation by 11β‐HSD1 seen in several 
inflammatory	 diseases.11,12,14,34,36,37 Whilst this study cannot 
accurately discriminate between the 11β‐HSD	 types	 1	 and	 2	
contributions	to	systemic	GC	metabolism,	 it	 is	unlikely	that	our	
findings	 are	 solely	 attributable	 to	 loss	 of	 renal	 cortisol	 inacti‐
vation by 11β‐HSD2.	 The	 inflammatory	 cytokines	 TNFα and 
IL‐1β,	which	accumulate	in	uraemia,	are	potent	inducers	of	11β‐
HSD1.9,11	Furthermore,	studies	in	human	hepatocytes	and	animal	





In	 this	 study,	 we	 demonstrate	 that	 diabetes,	 and	 HbA1c	
among	patients	with	diabetes,	 is	 associated	with	elevated	urine	
(THF+5αTHF)/THE	 in	CKD.	 The	 association	 of	 impaired	 glycae‐
mic	 control	 with	 shifts	 in	 cortisol	 metabolism	 remained	 after	
adjustment	 for	 age,	 sex,	 ethnicity,	 renal	 function	and	 inflamma‐
tion.	These	 results	 align	with	 a	 large	body	of	 evidence	 that	 has	
established	insulin	resistance	as	a	consequence	of	increased	11β‐
HSD1 activity in animal models and human disease.7,23,24,26‐29 The 
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and	 PKB/Akt	 to	 impede	 post‐receptor	 insulin	 signal	 transduc‐
tion.15,16	 In	 the	 same	 tissues,	 in	 vitro	experiments	have	demon‐
strated	the	capability	of	TNFα	and	IL‐1β	to	upregulate	11β‐HSD1,	






lipidaemia—for	which	 a	 proof	 of	 concept	 experiment	 in	 rodents	
has	already	been	successful.7
Urinary	 cortisol‐cortisone	 ratio	 exhibited	 a	 moderate	 cor‐
relation with renal 11β‐HSD2	expression	 in	a	previous	study	by	
Quinkler	et	al6.	An	association	between	renal	function	and	corti‐
sol‐cortisone	ratios	in	24	hour	urine	samples	has	been	described	
in some but not all studies.4,6,40	In	this	study,	we	did	not	identify	
any	 significant	 correlations	 between	 urinary	 cortisol‐cortisone	
ratios	with	eGFR,	nor	with	CRP	or	Hb1Ac.	These	divergent	results	
may	reflect	significant	heterogeneity	between	study	populations,	




TA B L E  2   Independent	determinants	of	11β‐HSD‐mediated	glucocorticoid	activation	(n	=	337)
Variable B SE β t P
Age	(y) 1.13 × 10−3 1.94 × 10−3 0.035 0.58 0.560
Sex
Male Reference
Female −0.143 0.058 −0.130 −2.47 0.014
Ethnicity
White Reference
South Asian 0.104 0.078 0.074 1.33 0.185
Black 0.208 0.094 0.119 2.20 0.028
Other −0.565 0.300 −0.099 −1.89 0.060
eGFR	(mL/min/1.73	m2) −1.76	×	10−3 1.34 × 10−3 −0.075 −1.31 0.191
Urine	ACR	(mg/mmol) 3.43 × 10−5 2.40 × 10−4 0.008 0.14 0.886
C‐reactive	protein	(mcg/ml) 6.72 × 10−3 2.14 × 10−3 0.172 3.14 0.002
HbA1c	(mmol/mol) 3.08 × 10−3 2.39 × 10−3 0.074 1.29 0.198
Multivariable	linear	regression	analysis	with	dependent	variable	loge‐transformed	urine	(THF+5αTHF)/THE.	Adjusted	R
2 =	0.083.	Exclusion	of	the	11	
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or	 that	 spot	 urines	 lack	 sufficient	 sensitivity	 to	 detect	 these	
changes.
Several strengths and limitations are worth noting about this study. 
The	observational	design	produced	results	that	demonstrate	associa‐
























potential	 contributions	 of	 the	 hypothalamic‐pituitary‐adrenal	 (HPA)	
axis	to	our	results.	Without	timed	serum	samples	or	urine	samples	from	
a	fixed	collection	period	for	our	cohort,	we	were	unable	to	control	di‐
rectly	 for	 systemic	 cortisol	 levels	or	HPA	axis	 activity.	Nevertheless,	
previous	studies	validated	the	specificity	of	urine	 (THF+5αTHF)/THE	
for	alterations	 in	11β‐HSD	activity	over	changes	 in	HPA	axis	activity	
and	 found	 no	 correlation	 between	 total	 GC	metabolite	 excretion	 as	
a	measure	of	HPA	axis	activity	and	renal	 function.4,6,31,32	Neither	do	
fluctuations	 in	 systemic	 cortisol	 interfere	 with	 urine	 (THF+5αTHF)/
THE.41	Importantly,	basal	cortisol	levels,	as	well	as	the	fraction	of	pro‐
tein	bound	cortisol	 (90%‐95%),	do	not	change	significantly	with	renal	
impairment.42,43	 We	 therefore	 argue	 that	 associations	 with	 urine	













Middle tertile High tertile
OR 95% CI P OR 95% CI P
Unadjusted 342 Ref. 1.36 0.77‐2.42 0.289 2.57 1.47‐4.47 0.001
Model	A 342 Ref. 1.30 0.70‐2.40 0.403 1.97 1.07‐3.62 0.029
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